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Abstract
Introduction We investigated the ability of a weekly intra-
articular injection of bone morphogenetic protein (BMP)-7 to
prevent osteoarthritis in rabbits with anterior cruciate ligament
transections.
Methods First, 36 knee joints were randomly divided into four
groups: 50, 500, 5,000 ng BMP-7, and control. Knee cartilage
was evaluated at 4, 8, and 12 weeks. Then, in order to control
for individual differences, 500 ng BMP-7 was injected into one
knee and phosphate-buffered saline (PBS) into the other, and
the two knees were compared at 4, 8, and 12 weeks (n = 5). For
pharmacokinetic analysis, cartilage was harvested at 1 hour and
1, 2, 4, and 7 days after knee injection of 500 ng BMP-7 or PBS
(n = 3).
Results Histological scores in the 500 and 5,000 ng BMP-7
groups were significantly better than those in the other groups
at 12 weeks. Matched pair analysis demonstrated that both
macroscopic and histological scores in the 500 ng BMP-7
group were better than those in the control group.
Immunohistochemical analysis revealed higher BMP-7
expression by chondrocytes in the BMP-7 injected knees.
Histology of whole knee and quantitative micro computed
tomography analysis showed that weekly injections of 500 ng
BMP-7 did not induce synovial fibrosis, ectopic bone, or
osteophyte formation. As detected by enzyme-linked
immunosorbent assay, BMP-7 concentration in the cartilage
tissue was still higher in the BMP-7 treated group 7 days after
the injection.
Conclusions Weekly intra-articular injections of BMP-7
inhibited progression of osteoarthritis. Obvious adverse effects
were not observed. BMP-7 concentration and expression in
cartilage were still higher 7 days after injection.
Introduction
Osteoarthritis of the knee is one of the leading causes of dis-
ability among elderly people. It is mainly caused by the break-
down and eventual loss of joint cartilage. For many years,
scientists have been searching for ways to intervene in the dis-
ease process and so retard or even prevent progression of
joint damage.
Bone morphogenetic protein (BMP)-7, also referred to as
osteogenic protein-1, has a profound effect on chondrocyte
metabolism by stimulating the synthesis [1-3], organization [4],
and retention [2,5] of matrix molecules. With increasing age
and progression of articular cartilage degeneration, the
expression level of endogenous BMP-7 decreases [6], sug-
gesting that a decrease in BMP-7 may play an important role
in the progression of cartilage degeneration. A recent study
[7] demonstrated that continuous intra-articular infusion of
BMP-7 had a protective effect on cartilage degeneration,
which suggests the possible utility of BMP-7 as a treatment for
human osteoarthritis.
We speculated that periodic knee injections of a small amount
of BMP-7 would suppress the loss of cartilage matrix and con-
sequently prevent osteoarthritis progression, without any
adverse drug effects. In this study, BMP-7 was injected weekly
into the knee joints of rabbits after anterior cruciate ligament
transection (ACLT), and the cartilage of the knee was evalu-
ated morphologically. The knees were also evaluated for any
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possible adverse effects of the BMP-7. Furthermore, BMP-7
concentration in cartilage was sequentially analyzed after intra-
articular injection of BMP-7. The overall results suggest that
weekly intra-articular injection of a small amount of BMP-7 is a
promising nonsurgical treatment for osteoarthritis, and that
BMP-7 is an interesting candidate structure/disease-modify-
ing osteoarthritis drug.
Materials and methods
Animals and injection of BMP-7
Skeletally mature female Japanese white rabbits (10 ± 2
months old) weighing an average of 3.2 kg (range 2.8 to 3.6
kg) were used in the experiments. This study was conducted
in accordance with a protocol approved by the Animal Com-
mittee of Tokyo Medical and Dental University. Animals under-
went bilateral ACLT under anesthesia induced by
intramuscular injection of 25 mg/kg ketamine hydrochloride
(Sankyo, Tokyo, Japan) and intravenous injection of 45 mg/kg
sodium pentobarbital (Dainippon Sumitomo Pharma, Osaka,
Japan). The knee joint was approached through a medial par-
apatellar incision, and the patella was dislocated laterally. The
anterior cruciate ligament was then transected with a sharp
blade, and the capsule was sutured to render it watertight, fol-
lowed by skin closure. All animals were allowed normal cage
activity.
Lyophilized 5% lactose-buffered recombinant human BMP-7
(rhBMP-7; Stryker Biotech, Hopkinton, MA, USA) was dis-
solved in phosphate-buffered saline (PBS). Aliquoted 50, 500,
or 5,000 ng BMP-7 in 200 μl PBS was administrated intra-
articularly with a 27-gauge needle on a 1.0 ml syringe through
the lateral infrapatellar area toward the intercondylar space of
the femur in each animal in a deep knee-flexed position. The
first injection was given immediately after ACLT; the second
and subsequent injections were administered once a week up
to 12 weeks. The final injection was administered a week
before the animals were killed, by an overdose of sodium
pentobarbital; the knee joints were then evaluated.
For evaluation of the optimal dose of BMP-7, 18 rabbits with
36 knees were used. All animals underwent bilateral ACLT.
The 36 knee joints were randomly assigned to one of four
groups: three doses (50, 500, or 5,000 ng) of BMP-7 or con-
trol (PBS alone).
For matched pair analyses of BMP-7, 15 rabbits with 30 knees
were used. The other three rabbits with six knees were used
for whole knee experiments conducted to investigate the intra-
articular influences of BMP-7. The dose of 500 ng was chosen
based on the previous results. In each of the 18 animals, BMP-
7 was injected into the right knee and PBS into the left, as a
control.
Gross morphological examination
Femoral condyles were dissected and stained with India ink.
Macroscopic pictures were taken using MPS-7 (Sugiura Lab-
oratory Inc., Tokyo, Japan), a dedicated medical photography
platform, and used for macroscopic evaluation. Digital images
were taken using a Nikon Coolpix 4500 digital camera (Nikon,
Tokyo, Japan). Gross findings were classified into six grades
(grade 1: intact articular surface; grade 2: minimal fibrillation;
grade 3: overt fibrillation; grade 4a: erosion of 0 to 2 mm;
grade 4b: erosion of 2 to 5 mm; and grade 4c: erosion of >5
mm) and scored accordingly [8]. Both the medial and lateral
femoral condyles were individually scored. Then, the two
scores were summed to obtain a cumulative macroscopic
osteoarthritis score. In a blinded manner, the assessment was
conducted by two independent examiners, who were blinded
to each other's findings and to the treatment group assign-
ment of the animals. Finally, the two scores from the examiners
were averaged to obtain an overall score.
Histological examination
The dissected distal femurs were fixed in a 4% paraformalde-
hyde solution after gross morphological examination. The
specimens were decalcified in 4% EDTA solution, dehydrated
with a gradient ethanol series, and embedded in paraffin
blocks. Based on macroscopic observation, 20 coronal sec-
tions per knee were carefully prepared so as to include the
most severely degenerated area. For whole knee specimens,
sagittal sections were stained with Masson's trichrome. Histo-
logical sections were visualized using an Olympus IX71 micro-
scope (Olympus, Tokyo, Japan) and PIXERA Viewfinder 3.0
software (Pixera Corporation, San Jose, CA, USA). Histologi-
cal sections were assessed in a blinded manner by two indi-
vidual examiners, who were unaware of the treatment group
assignment of the animals, and quantified using the advanced
grading methodology of the Osteoarthritis Research Society
International (OARSI) osteoarthritic cartilage histopathology
grading system [9].
Immunohistochemical analysis
Paraffin-embedded sections were deparaffinized in xylene,
rehydrated through graded alcohol, and immersed in PBS. The
samples were pretreated with 0.4 mg/ml proteinase K (DAKO,
Carpinteria, CA, USA) in Tris-HCl buffer for 15 minutes at
room temperature for antigen retrieval. Any residual enzymatic
activity was removed by washing with PBS, and nonspecific
staining was blocked by preincubation with PBS containing
10% normal horse serum for 20 minutes at room temperature.
Mouse monoclonal anti-BMP-7 antibody (12G3; 1:100 dilu-
tion; Stryker Biotech, Hopkinton, MA, USA) was placed on the
sections overnight at 4°C. After extensive washing with PBS,
the sections were incubated in the secondary antibody of
biotinylated horse anti-mouse IgG (Vector Laboratories, Burl-
ingame, CA, USA) for 30 minutes at room temperature. Immu-
nostaining was detected with VECTASTAIN ABC reagentAvailable online http://arthritis-research.com/content/10/5/R118
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(Vector Laboratories), followed by DAB staining. Counter-
staining was performed with methyl green.
Semi-quantitative analysis of synovial fibrosis
The whole knee specimens stained with Masson's trichrome
were analyzed in order to measure the rate of synovial fibrosis
in the infrapatellar fat pad (IPF) [10,11]. The area of the whole
IPF and blue stained area of collagen fibers was measured
using Scion Image software (Scion Corporation, Frederick,
MD, USA). The rate of fibrosis in IPF (% fibrosis) was calcu-
lated as the blue stained area divided by the whole IPF area ×
100.
Micro computed tomography scanning and 
quantification of osteophyte volume
All specimens were subjected to analysis using a high-resolu-
tion micro computed tomography scanner (ScanXmate-E090;
Comscantecno, Kanagawa, Japan). Osteophytes were manu-
ally traced and detected in 10 axial sections, interpolated,
reconstituted, and quantified using TRI/3D-BON software
(RATOC, Tokyo, Japan).
Pharmacokinetic analysis of BMP-7 in cartilage tissue
At 1 hour and 1, 2, 4, and 7 days after intra-articular injection
of 500 ng BMP-7 or PBS into normal knees, rabbits were
killed, and cartilage tissue from their knee joints was collected.
The cartilage was homogenized in CelLytic™ MT Mammalian
Tissue Lysis/Extraction Reagent (Sigma, St. Louis, MO, USA)
and the lysed samples were centrifuged for 10 minutes at
12,000 g. The supernatant was stored with protease inhibitor
cocktail (Sigma, St. Louis, MO, USA) and BMP-7 levels were
measured using a sandwich enzyme-linked immunosorbent
assay. Monoclonal 1B12 antibody (Stryker Biotech, Hopkin-
ton, MA, USA) was utilized as a coating antibody. Plates were
coated with 1 μg/well of this antibody in sodium carbonate-
bicarbonate buffer and incubated overnight at 4°C. Nonspe-
cific binding was blocked with 4% milk/borate-buffered saline
containing 0.05% Tween-20 (BBST) blocking buffer. Either
BMP-7 standard or cartilage extract was added to the plate
and incubated at 37°C for 1 hour. A second anti-BMP-7 anti-
body labeled with alkaline phosphatase (12G3-AP) was
applied at 1:100 dilution in sodium carbonate-bicarbonate
buffer and incubated at 37°C for 1 hour. After this incubation,
an alkaline phosphatase substrate, PNPP-phosphatase sub-
strate (Pierce, Rockford, IL, USA), was added and incubated
at room temperature for 30 minutes. To stop the reaction, 2 N
NaOH was added. The absorbance was detected and quanti-
tated by microplate reader Sunrise Remote (TECAN, Männed-
orf, Switzerland). The data were then processed in LS-
PLATEmanager software (Wako, Osaka, Japan).
Statistical analysis
All data are expressed as mean ± standard deviation. A non-
parametric Mann-Whitney U test was used to evaluate the sta-
tistical significance of differences in the macroscopic and
histologic results. A Wilcoxon's signed rank-sum test was
used to perform matched pair analyses. Interobserver variation
in gross morphologic grading was verified by measuring
agreement with the κ statistic. P values less than 0.05 were
considered statistically significant.
Results
Dose effect of BMP-7 for preventing the progression of 
osteoarthritis
After ACLT, 50, 500, or 5,000 ng BMP-7 in 200 μl PBS or
PBS alone was injected weekly into the knee joint. Macro-
scopic observation of femoral condyles at 12 weeks demon-
strated obvious surface irregularity in the control and 50 ng
BMP-7 groups, whereas a milder alteration in the articular sur-
face was observed in the 500 ng and 5,000 ng BMP-7 groups
(Figure 1a). No damage was caused by the needle. Histologi-
cally, cartilage matrix disappeared in the control and 50 ng
BMP-7 groups, whereas it was predominantly retained in the
500 ng and 5,000 ng BMP-7 groups (Figure 1b). The OARSI
osteoarthritis scores for histologic analysis were similar in all
four groups at 4 and 8 weeks; however, they were significantly
better in the 500 ng and 5,000 ng BMP-7 groups than in the
control group at 12 weeks (Figure 1c). These data indicate
that weekly injections of 500 ng and 5,000 ng BMP-7 pre-
vented the progression of osteoarthritis. There were no signif-
icant differences between the 500 ng and 5,000 ng groups.
The dose-response effect of BMP-7 reached a plateau at 500
ng, and therefore the dose of 500 ng BMP-7 was used in fur-
ther analyses.
Matched pair analyses: effect of BMP-7 on osteoarthritis 
progression
During the early stage of the investigation, we found that rab-
bits exhibited considerable individual variability in osteoarthri-
tis progression after ACLT. To examine the effect of BMP-7 on
osteoarthritis progression in a stricter manner, after the liga-
ments in the both knees were dissected, 500 ng BMP-7 in
200 μl PBS was injected into the right knee, and the same
amount of PBS was injected into the left knee of the same ani-
mal on a weekly basis.
Macroscopic observations on gross morphologic changes of
the femoral condyles in the control group revealed subtle car-
tilage lesions at 4 weeks, a slight progression at 8 weeks, and
obvious surface irregularity at 12 weeks (Figure 2a). On the
contrary, cartilage of the femoral condyles in the treatment
group appeared to be better throughout the study. Interest-
ingly, four out of five rabbits in the control side/group exhibited
erosions in both the lateral and medial femoral condyles at 12
weeks; however, in the 500 ng BMP-7 side/group, only two
rabbits exhibited erosions in the lateral femoral condyle, and
two other rabbits showed erosions in the medial femoral con-
dyle. In all animals, the macroscopic osteoarthritis score was
better in the BMP-7 injected knee than in the contralateral
control knee (Figure 2b). The interobserver agreement forArthritis Research & Therapy    Vol 10 No 5    Hayashi et al.
Page 4 of 9
(page number not for citation purposes)
grading of cartilage damage indicates high reproducibility (κ =
0.84).
Histologically, stainability with safranin-O in cartilage matrices
appeared to be similar in both the 500 ng BMP-7 and control
groups at 4 weeks (Figure 2c). At 8 weeks, in the control side/
group, cartilage became thinner or stainability with safranin-O
became worse than in the BMP-7 side/group. At 12 weeks,
cartilage lesions further worsened, and most of the knees in
the control side/group exhibited severe erosion or cartilage
defects in both the medial and lateral condyles. BMP-7
injected knees also developed erosive lesions; however, those
were limited either to the medial or to the lateral femoral con-
dyle. The OARSI osteoarthritis score was better at the BMP-7
side than at the contralateral control side in each rabbit at 12
weeks (Figure 2d). Matched pair analyses revealed that
weekly 500 ng BMP-7 injections slowed the progression of
osteoarthritis.
BMP-7 expression in cartilage of knee after weekly BMP-
7 injection
Immunohistochemical analysis showed that BMP-7 was barely
expressed in chondrocytes of the remaining cartilage in the
control knees. On the contrary, the rate of chondrocytes stain-
ing positive for BMP-7 was higher in the knees receiving treat-
ment with BMP-7 despite 7 days having passed since the last
injection (Figure 3).
Investigation of presumable adverse effects of BMP-7
It was hypothesized that repeated BMP-7 injections into the
knee joint might induce adverse effects such as synovial fibro-
sis, ectopic cartilage and bone formation, or osteophyte forma-
Figure 1
Evaluation of dose effect of BMP-7 for prevention of osteoarthritis progression in rabbit ACLT Evaluation of dose effect of BMP-7 for prevention of osteoarthritis progression in rabbit ACLT. (a) Representative macroscopic appearances of the 
distal portion of the femoral condyles at 12 weeks. Surface of the cartilage was stained with India ink to identify any fibrillation and erosion. Laterality 
is shown as lateral (L) and medial (M). Bar = 5 mm. (b) Representative histology of femoral condyles at 12 weeks. Distal femur was sectioned coro-
nally and stained with safranin-O. The most degenerated area of each sample is included. Bar = 50 μm. (c) Quantitation of histological analysis 
using the OARSI cartilage osteoarthritis histopathology grading system. The scores are displayed as average ± standard deviation (three knees). *P 
< 0.05, by Mann-Whitney U test. ACTL, anterior cruciate ligament transection; BMP, bone morphogenetic protein; OARSI, Osteoarthritis Research 
Society International.Available online http://arthritis-research.com/content/10/5/R118
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tion. Various techniques were used to screen for any possible
unwanted response.
For synovial fibrosis, fibrotic areas in the IPF were compared.
According to the quantitative analysis, the ratio of fibrotic area
in the BMP-7 treated knee was not higher than that in the con-
trol knee (Figure 4). We examined the area around the border
between cartilage and synovium, the area around the sutured
capsule, and the area around the dissected anterior cruciate
ligament carefully, but we did not detect ectopic cartilage for-
mation in the knees injected with BMP-7. For ectopic bone or
osteophyte formation, whole knee joints were evaluated by
micro computed tomography. No ectopic bone formation was
observed by three-dimensional reconstructed imaging (Figure
5a). Quantitative analysis showed that the volume of osteo-
phyte formation in the BMP-7 group was not more than that in
the control group at 12 weeks (Figure 5b,c). Based on these
results, it appears that BMP-7 did not induce any obvious
adverse effects.
Pharmacokinetic analysis of BMP-7 in cartilage tissue
BMP-7 levels in cartilage tissue were measured using sand-
wich enzyme-linked immunosorbent assay (Figure 6a). In con-
t r o l  k n e e s ,  B M P - 7  w a s  b a r e l y  d e t e c t e d  a t  a n y  o f  t h e
Figure 2
Matched pair analyses of the effect of BMP-7 on osteoarthritis progression Matched pair analyses of the effect of BMP-7 on osteoarthritis progression. (a) Macroscopic appearances of the femoral condyles at 4, 8, and 12 
weeks. To remove individual variability, both sides of the knees of the same individuals are shown. Surface of the cartilage was stained with India ink 
to identify any fibrillation and erosion. Laterality is shown as lateral (L) and medial (M). Bar = 5 mm. (b) Paired comparison in the macroscopic oste-
oarthritis score. The scores of the treatment and control knees (in the same animal) are displayed separately and connected with a line (five knees). 
*P < 0.05, by Wilcoxon's signed rank sum test. (c) Representative histology of femoral condyles. Both sides of the knees from the same individuals 
are shown. Medial femoral condyles (MFC) and lateral femoral condyles (LFC) were sectioned coronally and stained with safranin-O. Bar = 10 μm. 
(d) Paired comparison in quantitation of histological analysis using the OARSI cartilage osteoarthritis histopathology grading system (five knees). *P 
< 0.05 by Wilcoxon's signed rank sum test for paired samples. BMP, bone morphogenetic protein; OARSI, Osteoarthritis Research Society 
International.Arthritis Research & Therapy    Vol 10 No 5    Hayashi et al.
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observation times (Figure 6b). On the contrary, 1 hour after
BMP-7 injection BMP-7 was detected at high levels in carti-
lage; the level decreased by 60% 1 day after injection. BMP-
7 levels gradually decreased over time, and 7 days after the
last injection BMP-7 concentration in treated knees was still
higher than that in control knees.
Discussion
Experimental osteoarthritis induced by ACLT is one of the
most widely used models [12-14] and provides temporal pro-
gression of cartilage degeneration in the knee. One of the
characteristics of this model is that cartilage is affected initially
from medial femoral condyle and eventually extends over the
lateral femoral condyle [15]. This model alters both the magni-
tude and distribution of joint forces that are applied to the car-
tilage surface in vivo. Joint instability is the key factor for the
onset and/or progression of cartilage degeneration in human
osteoarthritis, and this model mimics that mechanism.
Because of the instability generated, it is a particularly chal-
lenging model for testing structure/disease-modifying osteoar-
thritis drugs, because the instability that caused the
osteoarthritis is still present even as the drug is being applied.
In animal cartilage defect models, several reports have shown
that implantation of a scaffold impregnated or mixed with
BMP-2 [16] or BMP-7 [17-21] can promote cartilage repair.
However, it is expected that a single administration of BMP will
not prevent progression of osteoarthritis induced by joint insta-
bility. To overcome this potential problem, an osmotic pump
was previously used [7]; however, from the standpoint of clin-
ical availability, periodic injections into the knee of BMP-7
would be more attractive. This may also allow the clinician flex-
ibility and options regarding the frequency or duration of the
BMP administration, and the potential to adjust the dose deliv-
ered into the knee, based on the stage of osteoarthritis.
Figure 3
Immunohistochemical analysis for BMP-7 in cartilage Immunohistochemical analysis for BMP-7 in cartilage. After anterior cru-
ciate ligament transection in both knees, 500 ng BMP-7 in 200 μl PBS 
was injected weekly into the right knee and the same amount of PBS 
was injected into the left knee. The remaining cartilage in medial femo-
ral condyles was evaluated at 12 weeks (7 days after the last injection). 
Higher magnifications are demonstrated in the right column. Bars = 10 
μm. BMP, bone morphogenetic protein; PBS, phosphate-buffered 
saline.
Figure 4
Evaluation of synovial fibrosis Evaluation of synovial fibrosis. After anterior cruciate ligament transec-
tion in both knees, 500 ng BMP-7 in 200 μl PBS was injected weekly 
into the right knee and the same amount of PBS was injected into the 
left knee. Whole knee sections stained with Masson's trichrome were 
evaluated at 12 weeks after ACLT. (a, c) Lower magnified histologies. 
Bar = 5 mm. (b, d) Higher magnified histologies of infrapatella fat pad. 
Bar = 1 mm. (e) Quantitation of fibrosis in infrapatellar fat pad. The val-
ues are displayed as average ± standard deviation (n = 3). BMP, bone 
morphogenetic protein; F, femur; IPF, infrapatellar fat pad; P, patella; 
PBS, phosphate-buffered saline; T, tibia.Available online http://arthritis-research.com/content/10/5/R118
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In this study, the BMP-7 injections were administered at 7-day
intervals. Our pharmacokinetic analysis demonstrated that
BMP-7 concentration in the cartilage tissue decreased rapidly
within 1 day and then the diminution rate decreased, but a
measurable level of BMP-7 was maintained for at least 7 days
after the injection. Furthermore, immunohistochemical analysis
demonstrated higher BMP-7 expression in chondrocytes from
the knee 7 days after the injection. There are three possible
mechanisms to explain why the effect of BMP-7 on chondro-
cytes persisted for more than 7 days after knee injection. First,
injected BMP-7 remained in the knee joint during activity for
over 7 days. Second, exogenous BMP-7 induced endogenous
BMP-7 expression in chondrocytes, and then chondrocytes
continued to express endogenous BMP-7 in an autocrine/
paracrine manner. Third, synovial tissue absorbed injected
BMP-7, and then synovial cells expressed endogenous BMP-
7 to enhance endogenous BMP-7 expression in chondrocytes
[22,23].
In this rabbit ACLT model, we examined the optimal dose of
BMP-7 for the prevention of osteoarthritis progression. First,
all knees of rabbits that underwent bilateral ACLT were ran-
domly assigned to one of four treatment groups. Although we
demonstrated that both 500 ng and 5,000 ng BMP-7 injec-
tions prevented the progression of osteoarthritis, there was no
Figure 5
Evaluation of ectopic bone and osteophyte formation Evaluation of ectopic bone and osteophyte formation. After anterior cru-
ciate ligament transection in both knees, 500 ng BMP-7 in 200 μl PBS 
was injected weekly into the right knee and the same amount of PBS 
was injected into the left knee. Knee joints were analyzed using a micro 
CT scanner at 12 weeks. (a) Representative three-dimensional CT 
images of BMP-7 treated and control knee. Lateral views show no obvi-
ous ectopic bone formation in BMP-7 injected side and control side. 
(b) Representative reconstructed CT images of distal femoral osteo-
phyte. Osteophytes were colored with yellow by image processing. Lat-
erality is shown as lateral (L) and medial (M). (c) Quantitation of 
osteophyte volume. The values are displayed as average ± standard 
deviation (n = 5). BMP, bone morphogenetic protein; CT, computed 
tomography; PBS, phosphate-buffered saline.
Figure 6
Pharmacokinetic analysis of BMP-7 in cartilage tissue Pharmacokinetic analysis of BMP-7 in cartilage tissue. (a) Outline for 
the analysis. Cartilage was obtained from knee joints at 1 hour and 1, 2, 
4, and 7 days after intra-articular injection of 500 ng BMP-7 or phos-
phate-buffered saline. Three joints for each time point were investi-
gated. (b) BMP-7 concentration per cartilage wet weight (ng/g). The 
values are shown as average ± standard deviation. BMP, bone morpho-
genetic protein.Arthritis Research & Therapy    Vol 10 No 5    Hayashi et al.
Page 8 of 9
(page number not for citation purposes)
significant difference between the two groups. We assume
that use of a higher-dose BMP-7 may increase the risk of
adverse effects including ectopic cartilage and bone forma-
tion, osteophytes, and synovial fibrosis in the knee joint. These
doses were much less than those used in other rabbit cartilage
studies previously conducted. Sellers and coworkers [16]
reported that 5 μg BMP-2 promoted healing of full-thickness
defects of articular cartilage. In another study employing a sim-
ilar design [24], 20 μg BMP-2 was used with a synthetic bio-
degradable carrier. The amount of 500 ng BMP-7 we used for
one injection was only 2.5% to 10% of that in the previous
reports.
The results of our first study indicate considerable individual
animal variability in osteoarthritis progression after ACLT. We
confirmed that the anterior cruciate ligament was completely
transected in every knee when the animals were killed, so the
injury was uniform in all animals. Therefore, another mecha-
nism must be responsible for the variability. We suspect that
differences in activity level between animals and genetic fac-
tors may be responsible.
In our second series of experiments, we wished to address the
inter-animal variability observed in the first study and to inves-
tigate the effect of BMP-7 on osteoarthritis progression in a
stricter manner. Therefore, we tested both treatments (500 ng
BMP-7 and PBS alone) in the same animal, with each knee
receiving a different treatment. This matched pair analyses
demonstrated that both macroscopic and microscopic scores
were better in the BMP-7 injected knees than in the contralat-
eral control knees in all rabbits at 12 weeks. This provides fur-
ther evidence that BMP-7 is effective in preventing OA
progression and that the previously observed results were
probably not due to the individual variability of rabbits.
The initial pathological change in osteoarthritis is character-
ized by a depletion of the cartilage extracellular matrix. Intra-
articular treatment with BMP-7 may enhance the synthesis of
new cartilage matrix, possibly preventing further degeneration.
Several in vitro studies indicated that BMP-7 promotes the
production of type II collagen and proteoglycans in normal
chondrocytes [1,4]. Even chondrocytes from osteoarthritic
patients have been shown to retain their ability to respond to
BMP-7, which also upregulates anabolic gene expression in
cartilage [2,3,5].
In consideration of drug efficacy and future clinical use, weekly
injections are an attractive option; however, further examina-
tion is needed to determine the optimal duration of the BMP-7
injection therapy for the osteoarthritic knee, based on several
additional in vivo studies.
Conclusion
Weekly intra-articular injections of BMP-7 inhibited osteoar-
thritis progression. BMP-7 concentration and expression in
cartilage were still elevated 7 days after BMP-7 injection. No
obvious adverse effects resulted from repeated intra-articular
injections of BMP-7.
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